AstraZeneca boosts open innovation efforts


Astrazeneca (AZ) has launched a new web portal, bringing together new and existing open innovation programmes. The aim is to make collaboration with academics, other companies, governments and non-government organisations easier.

Like a growing number of pharmaceutical companies, AZ already collaborates extensively with academics and other organisation. However, it wants to open up these programmes and encourage potential collaborators. AZ will offer access to its compound library, tool compounds for biological investigations, screening for target validation and various other services. There will also be rewards for researchers who suggest solutions for challenges the company is facing.

‘To push the boundaries of science and deliver new medicines to patients, we need to create a more permeable research environment,’ said AZ’s Mene Pangalos in a statement. ‘An essential part of that is making our knowledge and compounds more accessible.’

This move follows several similar initiatives from other companies: most notably GlaxoSmithKline, which has opened up extensive chunks of its compound libraries and runs collaborative drug discovery contests; Eli Lilly, which has ongoing target-based and phenotypic screening services available to potential collaborators; and a consortium of Japanese firms.


Related Content

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Data-sharing partnership for drug discovery

28 June 2013 Business

news image

Collaborative project aims to assist medicinal chemistry efforts

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers